Source link : https://newshealth.biz/health-news/moving-t-dxd-into-earlier-her2-positive-breast-cancer-care/
At the American Society of Clinical Oncology (ASCO) annual meeting, results from the DESTINY-Breast11 trial showed higher pathologic complete response (pCR) rates with a trastuzumab deruxtecan (T-DXd; Enhertu)-based neoadjuvant regimen compared with standard anthracycline-containing therapy in patients with high-risk HER2-positive early breast cancer. In this exclusive MedPage Today video, Jame Abraham, MD, of the Cleveland […]
The post Moving T-DXd Into Earlier HER2-Positive Breast Cancer Care first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-16 14:29:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8